Announced details
Regenerative medicine for serious diseases, including heart disease
The company submits and presents research at international conferences organized by AHA.
Organizer of the international conference BCVS 2026. Other information on its location, representative, business activities, capital and year of establishment is Not disclosed
Highest-rated award among submissions from Japan
Boston, Massachusetts, United States (conference venue)
No impact on business performance was disclosed
The company does not address Contract Value / Offering price.
BCVS 2026, organized by the American Heart Association (AHA)
| Item | Details |
|---|---|
| Names of Products / Services Covered | Regenerative medicine technology using iPS cells |
| Counterparty | American Heart Association (AHA) |
| Counterparty overview | Organizer of the international conference BCVS 2026. Other information on its location, representative, business activities, capital and year of establishment is Not disclosed |
| Relationship with the Company | The company submits and presents research at international conferences organized by AHA. |
| Launch date | 13–16 July 2026 (scheduled) |
| Applicable area | Regenerative medicine for serious diseases, including heart disease |
| Award/certification name | Highest-rated award among submissions from Japan |
| Location | Boston, Massachusetts, United States (conference venue) |
| Impact on Business Performance | No impact on business performance was disclosed |
| Source | BCVS 2026, organized by the American Heart Association (AHA) |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company’s technological capabilities and the advanced nature of its research results were highly evaluated at the conference.